Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer (review)

Oncology Reports

Volumn 5, Issue 6, 1998, Pages 1349-1361

  Kos, Janko ^a,b   Lah, Tamara T ^c  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b KRKA D D   (Slovenia)

^c NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

Author keywords

Cancer; Cathepsins; Cystatins; Diagnosis; Prognosis; Serum; Stefins

Indexed keywords

ALPHA 2 MACROGLOBULIN; CATHEPSIN; CYSTATIN; CYSTEINE PROTEINASE; KININOGEN; PAPAIN; STEFIN;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CELL INVASION; ENZYME SPECIFICITY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LYSOSOME; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; REVIEW;

EID: 0031685364     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.6.1349     Document Type: Review

References (145)

1. Uchiyama Y, Waguri S, Sato N, Watanabe T, Ishido K and Kominami E: Cell and tissue distribution of lysosomal cysteine proteinases, cathepsins B, H and L, and their biological roles. Acta Histochem Cytochem 27: 287-308, 1994.
2. Schmitt M, Jaenicke F and Graeff H: Protease, matrix degradation and tumor cell spread. Fibrinolysis 6 (Suppl 4): 1-17, 1992.
3. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
4. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvete J, Kramer M, Guncler WA, Janicke F and Graeff H: Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 266: 5147-5152, 1990.
5. Van der Stappen JW, Williams AC, Maciewicz RA and Paraskeva C: Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 67: 547-554, 1996.
6. Rasmussen HS and McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75: 69-75, 1997.
7. Brown PD and Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann Oncol 6: 967-974, 1995.
8. Satoh Y, Higashi T, Nouso K, Shiota T, Kinugasa N, Yoshida K, Uematsu S, Nakatsukasa H, Nishimura Y and Tsuji T: Cathepsin B in the growth of colorectal cancer: suppresive effect of leupeptin on the growth of DMH-induced rat colon neoplasm. Acta Med Okayama 50: 299-303, 1996.
9. Van Noorden CJ, Jonges TG, van Marie J, Bissell ER, Griffini P, Jans M, Snel J and Smith RE: Heterogenous suppression of experimentally induced metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin Exp Metastasis 16: 159-167, 1998.
10. Chapman HA, Riese JR and Shi GP: Emerging role for cysteine proteases in human biology. Annu Rev Physiol 59: 63-88, 1997.
11. Duffy MD, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen HJ: Urokinase-plasminogen activator, a marker for aggresive breast cancers. Preliminary report. Cancer 62: 531-533, 1988.
12. Thorpe S, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paulucci F, Pau P, Rasmussen BB and Rose C: Association between high concentrations of Mr 52000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014, 1989.
13. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le Doussal V, Tubiana-Hulin M and Brunet M: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272, 1992.
14. Rochefort H, Capony F and Garcia M: Cathepsin D: a proteinase involved in breast cancer metastasis. Cancer Metastasis Rev 9: 321-331, 1990.
15. Henry JA, McCarthy AL, Angus B, Westley BR, May F, Nicholson S, Cairns J, Harris AL and Horne C: Prognostic significance of esrogen-regulated protein, cathepsin D, in breast cancer. Cancer 65: 265-271, 1990.
16. Ravdin PM, Tandon AK, Allred DC, Clark GM, Fuqua SAW, Hilsenbeck SH, Chammness GC and Osborne CK: Cathepsin D by Western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 12: 467-474, 1994.
17. Lah TT, Kokalj-Kunovar M, Strukelj B, Pungercar J, Maganja D-B, Drobnic-Kosorok M, Kastelic L, Babnik J, Golouh R and Turk V: Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 50: 36-44, 1992.
18. Lah T and Kos J: Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 379: 125-130, 1998.
19. Turk B, Turk V and Turk D: Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 378: 141-150, 1997.
20. Kirschke H, Barrett AJ and Rawlings ND: Proteinases 1: lysosomal cysteine proteinases. In: Protein Profile 2. Sheterline P (ed.) Academic Press Ltd., London, pp 1587-1643, 1995.
21. Ulbricht B, Hagmann W, Ebert W and Spiess E: Differential secretion of cathepsins B and L from normal and tumor human lung cells stimulated by 12(S)-hydroxy-eicosatetraenoic acid. Exp Cell Res 226: 255-263, 1996.
22. Ulbricht B, Henny H, Horstmann H, Spring H, Faigle W and Spiess E: Influence of 12(S)-hydroxy-eicosatetraenoic acid (12(S)-HETE) on the localisation of cathepsin B and cathepsin L in human lung tumor cells. Eur J Cell Biol 74: 294-301, 1997.
23. Kobhnski JE and Sloane BF: Is altered localization of cathespin B causally related to malignant progression? In: Medical Aspects of Proteases and Protease Inhibitors. Katunuma N (ed.) IOS Press, Amsterdam. pp185-193, 1997.
24. Sloane BF: Suicidal tumor proteases. Nat Biotechnol 14: 826-827, 1996.
25. Turk B, Dolenc I, Zerovnik E, Turk D, Gubensek F and Turk V: Human cathepsin B is a metastable enzyme stabilized by specific ionic interactions associated with the active site. Biochemistry 33: 14800-14806, 1994.
26. Lah TT, Buck MR, Honn KV, Crissman JD, Rao NC, Liotta LA and Sloane BF: Degradation of laminin by human tumour cathepsin B. Clin Exp Metastasis 7: 461-468, 1989.
27. Buck MR, Karustis DG, Day NA, Honn KV and Sloane BF: Degradation of extracellular matrix proteins by human cathepsin B from normal and tumor tissues. Biochem J 282: 273-278, 1992.
28. Weiss RE, Liu BC-S, Ahlering T, Dubeau L and Droller MJ: Mechanism of human bladder tumor invasion: role of protease cathepsin B. J Urol 144: 798-804, 1990.
29. Keppler D and Sloane BF: Cathepsin B: multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein 49: 94-105, 1996.
30. Montcourier P, Mangeat PH, Salazar G, Morriset M, Sahuquet A and Rochefort H: Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicle. Cancer Res 50: 6045-6054, 1990.
31. Yan S, Sameni M and Sloane BF: Cathepsin B in human tumor progression. Biol Chem 379: 113-123, 1998.
32. Strohmaier AR, Porwol T, Acker H and Spiess E: Tomography of cells by confocal laser scanning microscopy and computer-assisted three-dimensional image reconstruction: localization of cathepsin B in tumor cells penetrating collagen gels in vivo. J Histochem Cytochem 45: 975-983, 1997.
33. Brown WJ, Goodhouse J and Farquhar MG: Mannose-6-phosphate receptors for lysosomal enzymes cycle between the Golgi complex and endosomes. J Cell Biol 103: 1235-1247, 1986.
34. Kasper D, Dittmer F, von Figura K and Pohlmann R: Neither type of mannose-6-phosphate receptor is sufficient for targeting of lysosomal enzymes along intracellular routes. J Cell Biol 134: 615-623, 1996.
35. Prence EM, Dong J and Sahagian GG: Modulation of the transport of a lysosomal enzyme by PDGF. J Cell Biol 110: 319-326, 1990.
36. Ackhar C, Gong Q, Frankfater A and Bajkowski AS: Differences in targeting and secretion of cathepsins B and L by BALB/3T3 fibroblasts and Moloney murine sarcoma virus transformed BALB/3T3 fibroblasts. J Biol Chem 264: 13650-13654, 1990.
37. Hanewinkel H, Glossl J and Kresse H: Biosynthesis of cathepsin B in cultured normal and I-cell fibroblasts. J Biol Chem 262: 12351-12355, 1987.
38. De Stefanis D, Demoz M, Dragonetti A, Houri JJ, Ogier-Denis E, Codogno P, Baccino FM and Isidoro C: Differentiation-induced changes in the content, secretion, and subcellular distribution of lysosomal cathepsins in human colon cancer HT-29 cell line. Cell Tissue Res 289: 109-117, 1997.
39. McIntyre GF and Erickson AH: The lysosomal proenzyme receptor that binds procathepsin L to microsomal membranes at pH 5.0 is a 43-kDa internal membrane protein. Proc Natl Acad Sci USA 90: 10588-10592, 1993.
40. Rijnboutt S, Aerts HM, Geuze HJ, Tager JM and Strous GJ: Mannose 6-phosphate-independent membrane association of cathepsin D, glucocerebrosidase, and sphingolipid-activating protein in HepG2 cells. J Biol Chem 266: 4862-4868, 1991.
41. Capony F, Braulke T, Rougeot C, Roux S, Montcourrier P and Rochefort H: Specific mannose-6-phosphate receptor-independent sorting of pro-cathepsin D in breast cancer cells. Exp Cell Res 215: 154-163, 1994.
42. Ren WP and Sloane BF: Cathepsins D and B in breast cancer. In: Mammary Tumor Cell Cycle, Differentiation and Metastasis. Dickson R and Lippman M (eds.) Kluwer Academic Publ., pp325-352, 1996.
43. Honn KV, Timar J, Rozhin J, Bazaz R, Sameni M, Ziegler G and Sloane BF: A lipoxygenase metabolite, 12-(S)-HETE, stimulates protein kinase C-mediated release of cathepsin B from malignant cells. Exp Cell Res 214: 120-130, 1994.
44. Kornfeld S: Lysosomal enzyme targeting. Biochem Soc Trans 18: 367-374, 1990.
45. Mort JS and Recklies AD: Interrelationship of active and latent secreted human cathepsin B precursor. Biochem J 233: 57-63, 1986.
46. Rozin J, Sameni M, Ziegler G and Sloane BF: Pericellular pH affects distribution and secretion of Cat B in malignant cells. Cancer Res 54: 6517-6525, 1994.
47. Corticchiato O, Cajot JF, Abrahamson M, Chan SJ and Keppler D: Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int J Cancer 52: 645-652, 1992.
48. Heidtmann HH, Salge U, Abrahamson M, Bencina M, Kastelic L, Kopitar-Jerala N, Turk V and Lah T: Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin Exp Metastasis 15: 368-381, 1997.
49. Lah TT, Calaf G, Kalman E, Shinde G, Somers R, Estrada S, Salero E, Russo J, Jarocz D, Zabrecky J and Daskal I: Differential regulation of cathepsins D, B and L in transformed human breast epithelial cells (HBEC) with increased invasiveness. Breast Cancer Res Treat 39: 221-233, 1996.
50. Brouillet JP, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J, Mani JC and Rochefort H: Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer 79: 2132-2136, 1997.
51. Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Broulliet J-P and Rochefort H: Biological and clinical significance of cathepsin D in breast cancer metastasis. Stem Cells 14: 642-650, 1996.
52. Maciewicz RA, Wardale RJ, Etherington DJ and Paraskeva C: Immunodetection of cathepsins B and L present and secreted from human pre-malignant and malignant colorectal tumor cell lines. Int J Cancer 43: 478-486, 1989.
53. Berquin IM and Sloane BF: Cysteine proteases and tumor progression. Perspect Drug Disc Design 2: 371-388, 1994.
54. Luethgens K, Gabrijelcic D, Turk V, Ebert W, Trefz G and Lah T: Cathepsin B and cysteine proteinase inhibitors in bronchoalveolar lavage fluid of lung cancer patients. Cancer Detect Prev 17: 387-397, 1993.
55. Lah TT, Kokalj-Kunovar M, Kastelic L, Babnik J, Stolfa A, Rainer S and Turk V: Cystatins and stefins in ascites fluid from ovarian carcinoma. Cancer Lett 61: 243-253, 1991.
56. Gabrijelcic D, Svetic B, Spaic D, Skrk J, Budihna M, Dolenc I, Popovic T, Cotic V and Turk V: Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 30: 69-74, 1992.
57. Makarewicz R, Drewa G, Szymanski W and Skonieczna Makarewicz I: Cathepsin B in predicting the extend of cervix carcinoma. Neoplasma 42: 21-24, 1995.
58. Leto G, Tuminello FM, Pizzolanti G, Montallo G, Soresi M and Gebbia N: Lysosomal cathepsins B and L and stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncology 54: 79-83, 1997.
59. Leto G, Tuminello FM, Pizzolanti G, Montallo G, Soresi M, Carroccio A, Ippolito S and Gebbia N: Lysosomal aspartic and cysteine proteinase serum level in patients with pancreatic cancer or pancreatitis. Pancreas 14: 22-27, 1997.
60. Kos J, Nielsen HJ, Krasovec M, Christensen IJ, Cimerman N, Stephens RW and Brunner N: Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 4: 1511-1516, 1998.
61. Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N and Vrhovec I: Cathepsins B, H, L, and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3: 1815-1822, 1997.
62. Schweiger A, Stabuc B, Popovic T, Turk V and Kos J: Enzyme linked immunosorbent assay for the detection of total cathepsin H in human tissue cytosols and sera. J Immunol Methods 201: 165-172, 1997.
63. Hirano T, Manabe T and Takeuchi S: Serum cathepsin B levels and urinary excretion of cathepsin B in the cancer patients with remote metastasis. Cancer Lett 70: 41-44, 1993.
64. Mikkelsen T, Van PS, Ho KL, Sameni M, Sloane BF and Rosenblum ML: Immunolocalisation of cathepsin B in human glioma: implications for tumor invasion and angiogenesis. J Neurosurg 83: 285-290, 1995.
65. Turk V and Bode W: The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 285: 213-219, 1991.
66. Rawling ND and Barrett AJ: Evolution of proteins of the cystatin superfamily. J Mol Evol 30: 60-71, 1990.
67. Hiwasa T, Yokoyama S, Ha JM, Noguchi S and Sakiyama S: c-Ha-ras gene products are potent inhibitors of cathepsins B and L. FEBS Lett 211: 23-36, 1987.
68. Bode W, Engh R, Musil DJ, Thiele U, Huber R, Karshikov A, Brzin J, Kos J and Turk V: The 2.0A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. EMBO J 7: 2593-2599, 1988.
69. Machleidt W, Thiele U, Laber B, Assfalg-Machleidt I, Esterl A, Wiegand G, Kos J, Turk V and Bode W: Mechanism of inhibition of papain by chicken egg white cystatin. FEBS Lett 243: 234-238, 1989.
70. Stubbs MT, Laber B, Bode W, Huber R, Jerala R, Lenarcic B and Turk V: The refined 2.4 A X-ray crystal structure of recombinant human stefin B in complex with the cysteine proteinase papain: a novel type of proteinase inhibitor interaction. EMBO J 9: 1939-1947, 1990.
71. Dieckmann T, Mitschang L, Hofman M, Kos J, Turk V, Auerswald EA, Jaenicke R and Oschkinat H: The structures of native phosphorylated chicken cystatin and of a recombinant unphosphorylated variant in solution. J Mol Biol 234: 1048-1059, 1993.
72. Martin JR, Craven CJ, Jerala R, Kroon-Zitko L, Zerovnik E, Turk V and Waltho JP: The three dimensional solution structure of human stefin A. J Mol Biol 246: 331-343, 1995.
73. 2-98 M65L, by NMR spectroscopy. A possible role of the interactions between the N- and C-termini to maintain the inhibitory active form of cystatin A. Biochemistry 34: 14637-14648, 1995.
74. Rinne A, Rasanen O, Jarvinen M, Dammert K, Kallionen M and Hopsu-Havu VK: Occurrence of acidic and neutral cysteine proteinase inhibitors in epidermal malignancies: immunohistochemical study. Acta Histochem 74: 75-79, 1984.
75. Hopsu-Havu VK, Joronen I, Jarvinen M, Rinne A and Aalto M: Cysteine proteinase inhibitors produced by mononuclear phagocytes. Cell Tissue Res 236: 161-164, 1984.
76. Jarvinen M, Rinne A and Hopsu-Havu VK: Human cystatins in normal and diseased tissues: a review. Acta Histochem 82: 5-18, 1989.
77. Lenarcic B, Kos J, Dolenc I, Lucovnik P, Krizaj I and Turk V: Cathepsin D inactivates cysteine proteinase inhibitors cystatins. Biochem Biophys Res Commun 154: 765-772, 1988.
78. Barrett AJ, Rawlings ND, Davies ME, Machleidt W, Salvesen G and Turk V: Cysteine proteinase inhibitors of cystatin superfamily. In: Proteinase Inhibitors. Barrett AJ and Salvesen G (eds.) Elsevier, Amsterdam. pp515-569, 1986.
79. Henskens YMC, Veerman ECI and Amerogen AVN: Cystatins in health and disease. Biol Chem 377: 71-86, 1996.
80. Pennachio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, D'Amato E, Ramirez L, Faham M, Koskinemi M, Warrington JA, Norio R, De la Chapelle A, Cox DR and Myers RM: Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271: 1731-1734, 1996.
81. Lindahl P, Nycander M, Ylienjarvi K, Pol E and Bjork I: Characterisation by rapid-kinetic and equilibrium methods of the reaction between N-terminally truncated forms of chicken cystatin and the cysteine proteinases papain and actinidin. Biochem J 286: 165-171, 1992.
82. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindström V and Grubb A: Serum cystatin C. determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40: 1921-1926, 1994.
83. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO and Price CP: Serum cystatin C by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47: 312-318, 1995.
84. Grubb A, Jensson O, Gudmunsson G, Arnason A, Löfberg H and Malm J: Abnormal metabolism of γ-trace alkaline microprotein. The basic defection in hereditary cerebral haemorrhage with amyloidosis. N Engl J Med 311: 1547-1549, 1984.
85. Sloane BF, Moin K and Lah TT: Lysosomal enzymes and their endogenous inhibitors in neoplasia. In: Biochemical and Molecular Aspects of Selected Cancers. Pretlow TG and Pretlow TP (eds.) Academic Press, New York, pp411-466, 1994.
86. Buttle DJ, Abrahamson M, Burnett D, Mort JS, Barrett AJ, Dando PM and Hill SL: Human sputum cathepsin B degrades proteoglycan, is inhibited by alfa2-macroglobulin and is modulated by neutrophil elastase cleavage of cathepsin B precursor and cystatin C. Biochem J 276: 325-331, 1991.
87. Skaleric U, Babnik J, Curin V, Lah T and Turk V: Immunochemical quantitation of cysteine proteinase inhibitor cystatin C of inflamed human gingiva. Arch Oral Biol 34: 301-305, 1989.
88. Bollengier F: Cystatin C, alias post-γ-globulin: a marker for multiple sclerosis? J Clin Chem Clin Biochem 25: 589-593, 1987.
89. Brzin J, Popovic T and Turk V: Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun 118: 103-109, 1984.
90. Cattaneo A, Sansot JL, Prevot D, Blanc C, Manuel Y and Colle A: Cystatin C (post γ globulin) in serum from patients with autoimmune diseases. In: Cysteine Proteinases and their Inhibitors. Turk V (ed.) Walter de Gruyter, Berlin, New York, pp507-516, 1986.
91. Collé A, Tavera C, Prevot D, Leung-Tack J, Thomas Y, Manuel Y, Benveniste J and Leibowitch J: Cystatin C levels in sera of patients with human immunodeficiency virus infection J Immunoassay 13: 47-60, 1992.
92. Muller-Esterl W: Kininogens, kinins and kinship. Thromb Haemost 61: 2-6, 1989.
93. Turk V and Bode W. Human cysteine proteinases and their inhibitors, stefins and cystatins. In: Innovations in Proteases and their Inhibitors. Aviles FX (ed.) Walter de Gruyter, Berlin, pp47-59, 1993.
94. Muller-Esterl W, Iwanaga S and Nakanishi S: Kininogens revisited. Trends Biochem Sci 11: 336-339, 1986.
95. Salvesen G, Parkes G, Abrahamson M, Grubb A and Barrett AJ: Human low molecular weight kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J 234: 429-432, 1986.
96. Starkey PM, Fletcher TC and Barrett AJ: Evolution of α2-macroglobulin. Purification and characterisation of protein homologous with human α2-macroglobulin from plaice (Pleuromides platessa) plasma. Biochem J 205: 97-104, 1982.
97. Nagler DK, Storer AC, Portaro FCV, Carmona E, Juliana L and Menard R: Major increase in endopeptidase activity of human cathepsin B upon removal of occluding loop contacts. Biochemistry 36: 12608-12615, 1997.
98. Koga H, Mori N, Yamada H, Nishimura Y, Tokuda K, Kato K and Imoto T: Endo- and aminopeptidase activities of rat cathepsin H. Chem Pharm Bull 40: 965-972, 1992.
99. Alvaikko M, Aine R, Rinne A, Jarvinen M, Blanco G, Apaja-Sarkkinen M and Hopsu-Havu VK: Behaviour of dendritic reticulum cells possessing immunoreactive acid cysteine proteinase inhibitor in human lymphoid secondary follicles and in follicular centre cell lymphomas. Int J Cancer 35: 3199-3225, 1985.
100. Soderstrom KO, Rinne R, Hopsu-Havu VK, Jarvinen M and Rinne A: Hodgkin's disease: a malignancy of follicular dendritic cells. Lancet 343: 422-423, 1994.
101. Hawley-Nelson P, Roop DR, Cheng CK, Krieg TM and Yuspa SH: Molecular cloning of mouse epidermal cystatin A and detection of regulated expression in differentiation and tumongenesis. Mol Carcinol 1: 202-211, 1989.
102. Kartasova T, Corneilssen BJC, Belt P and van de Putte P: Effects of UV. 4-NQO and TPA on gene expression in cultured human epidermal keratmocytes. Nucleic Acids Res 15: 5945-5962, 1987.
103. Lah TT, Kos J, Blejec A, Frkovic-Gergios S, Golouh R, Vrhovec I and Turk V: The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathol Oncol Res 3: 89-99, 1997.
104. Kuopio T, Kankaanranta A, Jalava P, Kronquist P, Kotkansalo T, Weber E and Collan Y: Inhibitor cystatin A in breast cancer. Cancer Res 58: 423-436, 1998.
105. Lah TT, Clifford JL, Helmer KM, Day NA, Moin K, Honn KV, Crissman JD and Sloane BF: Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma. Biochim Biophys Acta 993: 63-73, 1989.
106. Kos J, Smid A, Kraseve M, Svetic B, Lenarcic B, Vrhovec I, Skrk J and Turk V: Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem 376: 401-405, 1995.
107. Ebert E, Werle B, Juelke B, Kopkar-Jerala N, Kos J, Lah T, Abrahamson M, Spiess E and Ebert W: Expression of cysteine proteinase inhibitors stefin A, stefin B and cystatin C in human lung tumors. Adv Exp Med Biol 421: 259-265, 1997.
108. Budihna M, Strojan P, Smid L, Skrk J, Vrhovec I, Rudolf Z, Zargi M, Krasovec M, Svetic B, Kopitar-Jerala N and Kos J: Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol Chem 377: 385-390, 1996.
109. Siewinski M, Krecicki T, Jarmulowicz J and Berdowska I: Cysteine proteinase inhibitors in serum of patients with head and neck tumours. Diagn Oncol 2: 323-326, 1992.
110. Graeff H, Harbeck N, Pache L, Wilhem O, Janicke F and Schmitt M: Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis 6: 45-53, 1992.
111. McGuire WL, Tandon AK, Allred DC, Chamnes GC and Clark GM: Commentaries: how to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82: 12, 1990.
112. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Jänicke F, Pache L and Graeff H: Prognostic values of the cysteine protease cathepsin B and L in human breast cancer. Clin Cancer Res 1: 741-746, 1995.
113. Thomssen C, Oppelt P, Janicke F, et al: Identification of low-risk node negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L. Anticancer Res (In press).
114. Budihna M, Skrk J, Zakotnik B, Gabrijelcic D and Lindner J: Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. Eur J Cancer 31: 661-664, 1995.
115. Foekens J, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, Meijer-van-Gelder M, Henzen-Xogmans SC, Putten WLJ and Klijn JGM: Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 16: 1013-1021, 1998.
116. Ebert W, Knoch H, Werle B, Trefz G, Muley T and Spiess E: Prognostic value of increase lung tumor tissue cathepsin B. Anticancer Res 14: 895-890, 1994.
117. Knoch H, Werle B, Ebert W and Spiess E: Imbalance between cathepsin B and cysteine proteinase inhibitors is of prognostic significance in human lung cancer. Int J Oncol 5: 77-85, 1994.
118. Sukoh N, Abe S, Ogura S, Isobe H, Takekawa H and Inoue K: Immunohistochemical study of cathepsin B. Cancer 74: 46-51, 1994.
119. Inoue T, Ishida K, Sugio K and Sugimachi K: Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. Cancer Res 54: 6133-6136, 1994.
120. Mori M, Kohli A, Baker SP, Savas and Fraire AE: Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful? Mod Pathol 10: 572-577, 1997.
121. Werle B, Julke B, Lah T, Kos J, Spiess E and Ebert W: Cathepsin B and cathepsin L: prognostic factors in human lung cancer. In: Proteolysis in Cell Function. Hopsu-Havu VK, Jarvinen M and Kirschke H (eds.) IOS Press, Amsterdam. pp472-478, 1997.
122. Werle B, Julke B, Lah T, Spiess E and Ebert W: Cathepsin B fraction active at physiological pH of 7.5 is of prognostic significance in squamous cell carcinoma of human lung. Br J Cancer 75: 1137-1143, 1997.
123. Smid L, Strojan P, Budihna M, Skrk J, Vrhovec J, Zargi M and Kos J: Prognostic value of cathepsins B, D, and stefins A and B in laryngeal carcinoma. Eur Arch Otolaryngol 254: 150-153, 1997.
124. Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL and Rao JS: Over-expression and localisation of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 13: 49-56, 1995.
125. Rempel SA, Rosenblum ML, Mikkelsen T, Van PS, Ellis KD, Golembieski WA, Sarneni M, Rozhin J, Ziegler G and Sloane BF: Cathepsin B expression and localisation in glioma progression and invasion. Cancer Res 54: 6027-6031, 1994.
126. Sivaparvathi M, Yamamoto M, Nicolson GL, Gokaslan ZL, Fuller GN, Liotta LA, Sawaya R and Rao JS: Expression and immunohistochemical localisation of cathepsin L during the progression of human gliomas. Clin Exp Metastasis 14. 27-34, 1996.
127. Sivaparvathi M, Sawaya R, Gokaslan ZL, Chintala KS and Rao JS: Expression and the role of cathepsin H in human glioma progression and invasion. Cancer Lett 104: 121-126, 1996.
128. Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M and Miyakawa I: Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol Oncol 56: 357-361, 1995.
129. Warwas M, Haczynska H, Gerber J and Nowak M: Cathepsin B-like activity as a serum tumor marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem 35: 301-304, 1997.
130. Makarewicz R and Drewa G: A possible application of cathepsin B activity determination for estimating the spread of the cervix uteri carcinoma. Acta Biochim Pol 43: 521-524, 1996.
131. Bhuvarahamurthy V and Govindasamy S: Extracellular matrix components and proteolytic enzymes in uterine cervical carcinoma. Mol Cell Biochem 144: 35-43, 1995.
132. Kos J, Stabuc B, Krasovec M, Schweiger A, Svetic B, Kopitar-Jerala N, Ocvirk J, Cimerman N, Rudolf Z and Vrhovec I: Lysosomal proteases cathepsins B, H, L and their inhibitors stefin A and cystatin C in sera of patients with metastatic melanoma. In: Molecular Oncology Today. Skrk J and Osmak M (eds.) Croatian League against Cancer, Zagreb, pp97-103, 1996.
133. Vollmer RT: Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Annu 24: 383-470, 1989.
134. Sirott MN, Bajorin DF and Wong GY: Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer 72: 3091-3098, 1993.
135. Keppler D, Fondaneche MC, Dalet-Fumeron V, Pagano M and Burtin P: Immunohistochemical and biochemical study of a cathepsin B like proteinase in human colonic cancers. Cancer Res 48: 6855-6862, 1988.
136. Sheahan K, Shuja S and Murnane MJ: Cysteine protease activities and tumor development in human colorectal carcinoma Cancer Res 49: 3809-3814, 1989.
137. Emmert-Buck MR, Roth MJ, Zhuang Z, Champo E, Rozhin J, Sloane BF, Liotta LA and Stetler-Stevenson WG: Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol 145: 1285-1290, 1994.
138. Murnane MJ, Sheahan K, Ozdemirli M and Shuja S: Stagespecific increases in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res 51: 1137-1142, 1991.
139. Murnane MJ, Shuja S, Del Re E, Cai J, Iacobuzio-Donahue C and Klepeis V: Characterizing human colorectal carcinomas by proteolytic profile. In Vivo 11: 209-216, 1997.
140. Leto G, Tumminello FM, Resso A, Pizzolanti G, Bazen V and Gebia N: Cathepsin D activity levels in colorectal cancer: correlation with cathepsin B and L and other biological and clinical parameters. Int J Oncol 5: 509-515, 1994.
141. Campo E, Munoz J, Miquel R, Palacin A, Cardesa A and Sloane BF: Cathepsin B expression in colorectal carcinoma correlates with tumor progression and shortened patient survival. Am J Pathol 145: 301-309, 1994.
142. Recklies AD, Tiltman KJ, Stoker AM and Poole AR: Secretion of proteinases from malignant and nonmalignant human breast tissue. Cancer Res 40: 550-561, 1980.
143. Dufek V, Jirasek V, Kral V, Matous B and Drazma E: Changes in serum cathepsin B-like activity in patients with colorectal cancer. Neoplasma 32: 51-57, 1985.
144. Krepela E, Kasafirek E and Novak K: Increased cathepsin B activity in human lung tumours. Neoplasma 32: 51-58, 1990.
145. Mikulewicz W, Berdowska I, Jarmulowicz J and Siewinski M: Decrease in vivo of cysteine endopeptidases in blood of patients with tumor of larynx. Anticancer Drugs 4: 341-344, 1993.